Induction of RAD51 nuclear foci after neoadjuvant chemotherapy and PARP inhibition can measure the homologous recombination functionality in breast cancer biopsies20,33–36, with an association to loss of heterozygosity measures of HR deficiency34,37. The gene discussed is PARP1; the disease is breast carcinoma.